Nuformix (LSE:NFX), a pharmaceutical development company targeting fibrosis and oncology through drug repurposing, reported positive results from a preclinical study of NXP002, its lead inhaled treatment candidate for idiopathic pulmonary fibrosis (IPF) and related lung diseases.
The study followed a placing announced on 11 March and was designed to generate data for both further development and questions raised by prospective licensing partners.
Researchers confirmed NXP002 can be nebulised across a wide dose range and showed substantial, dose-related pulmonary exposure, reaching lung concentrations within the range expected to provide pharmacological activity based on the company's earlier studies in human IPF lung tissue.
The drug also attenuated bleomycin-induced expression of alpha-smooth muscle actin, a biomarker linked to the fibrotic lung phenotype, across all doses tested, offering what the company calls surrogate evidence of target engagement in vivo.
Dan Gooding, Executive Director, said a key question from partner discussions has been whether inhaled NXP002 can achieve efficacious exposures "while maintaining an appropriate safety margin", and that the new data provide "a significantly stronger basis" for defining that therapeutic window.
The results support progression toward non-GLP dose-range-finding studies, while separate work continues on the specific biological pathways behind NXP002's anti-fibrotic activity.
Nuformix will present the findings and continue partnering talks at the European Respiratory Society Congress in Barcelona, running from 5 to 9 September.
News Intelligence what this means for the company
Nuformix reported that its inhaled IPF candidate NXP002 achieved lung concentrations in a preclinical nebuliser study consistent with expected therapeutic activity and showed dose-dependent suppression of a fibrosis biomarker. The data directly address a key licensing partner concern—whether inhaled dosing can hit efficacious exposures safely—and position the company to advance toward dose-range-finding studies and continue partnership discussions at a September respiratory congress. However, this remains preclinical validation; clinical proof of efficacy in patients remains years away.
The preclinical win removes a technical hurdle to partnering and validates the inhaled route, but Nuformix's path to value depends entirely on securing a licensing deal or raising capital to fund clinical trials. With only £930,283 in cash as of 31 March, the company cannot fund Phase 1 or later studies alone and must convert these data into a partnership before runway expires.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
